Vanderbilt-Ingram Cancer Center

Clinical Trial COGAALL0932

Title

Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)

Principal Investigator(s)

Haydar Frangoul

Details

• Protocol No. COGAALL0932
• Open Date: 11/11/2010
• Staging: Phase III
• Age Group: Children
• Scope: National
• Objective: To determine if a Maintenance regimen containing weekly oral methotrexate at 40 mg/m2/week will result in an improved disease free survival (DFS) compared to that containing weekly oral methotrexate at 20 mg/m2/week in the AR subset of patients with Standard Risk B-Precursor ALL. To determine whether a reduced-pulses Maintenance regimen with vincristine/dexamethasone pulses delivered every 12 weeks can be used without adversely impacting DFS as compared to pulses given every 4 weeks in the AR subset of patients with Standard Risk B-precursor ALL. To confirm that patients in the LR subset of Standard Risk B-precursor ALL, based on clinical and cytogenetic features and minimal residual disease (MRD) criteria, can attain a 5-year DFS of at least 95% with either a P9904-based regimen that includes 6 courses of intermediate dose methotrexate without alkylating agents or anthracyclines, or an outpatient based regimen identical to that of AR patients with reduced vincristine/dexamethasone pulses at 12 week intervals during Maintenance. To provide standardized treatment and enhanced supportive care to children with SR DS-ALL in order to improve outcomes and facilitate further study of this biologically and clinically unique patient subgroup.
• Disease Sites: Pediatrics; Leukemia
• Therapies: Chemotherapy - cytotoxic; Therapy (NOS)
• Drugs: None Specified
• Participating Institutions: Vanderbilt University
• Secondary Protocol No: AALL0932

Description

Eligibility

Learn More

• Call toll-free number: 1-800-811-8480
• Use our Online self–referral form
• Print this page for your doctor